X
X
Total 667546 Results
| Label | Description | ILX | Version | Created CID | Modified Time | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Amygdala of CIVM postnatal rat brain atlas | The amygdala is most easily segmented in the coronal plane of a diffusion-weighted image (DWI). This structure may be completely indistinguishable from surrounding regions on T2-weighted MRI. The rostral aspect of the amygdala begins as a light (low diffusivity) region just ventral to the dark (high diffusivity), ellipsoid, diagonal domain at roughly the level of the optic chiasm. Moving caudally, the lateral border of the amygdala is distinguishable from the adjacent cortex based on the dark appearance of layer 2 of the piriform cortex. The medial extent is easily identified based on the dark border created by the lateral hypothalamus and diagonal domain. The dorsal border of the amygdala with the striatum is defined by the start of the striations that define the caudate/putamen. The border with the hippocampus is equally straightforward due to the dark appearance of the alveus. The caudal border of the amygdala is a circular bulge of dark tissue on the ventral-most part of the allocortex (the posteromedial cortical amygdaloid nucleus), which emerges at around the level of the genu of the corpus callosum. | ILX:0100580 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amygdala of Macaque | ILX:0100581 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Amygdalo-entorhinal transition area of RHA11 | Cytoarchitectural field located between the ventral-intermediate entorhinal area (VIE) and the amygdalohippocampal transition area. The former is caudal and the latter is anterior to AE. Laterally, AE borders with the dorsal-intermediate entorhinal area (DIE), while medially it abuts on the periamygdaloid cortex. | ILX:0100582 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amyl Nitrite | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Like other alkyl nitrites, amyl nitrite is bioactive in mammals, being a vasodilator which is the basis of its use as a prescription medicine. As an inhalant, it also has psychoactive effect which has led to illegal drug use. Pharmacology: Amyl nitrite, in common with other alkyl nitrites, is a potent vasodilator. It expands blood vessels, resulting in lowering of the blood pressure. Alkyl nitrite functions as a source of nitric oxide, which signals for relaxation of the involuntary muscles. Physical effects include decrease in blood pressure, headache, flushing of the face, increased heart rate, dizziness, and relaxation of involuntary muscles, especially the blood vessel walls and the anal sphincter. There are no withdrawal symptoms. Mechanism of action: Amyl nitrite's antianginal action is thought to be the result of a reduction in systemic and pulmonary arterial pressure (afterload) and decreased cardiac output because of peripheral vasodilation, rather than coronary artery dilation. As an antidote (to cyanide poisoning), amyl nitrite promotes formation of methemoglobin, which combines with cyanide to form nontoxic cyanmethemoglobin. Drug type: Approved. Small Molecule. Drug category: Vasodilator Agents | ILX:0100583 | 5 | scicrunch | 08/24/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | troy sincomb |
| Amylin | ILX:0100584 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Amyloid Aggregate | Insoluble fibrous protein aggregation sharing specific structural traits. | ILX:0100585 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amyloid Fibril | A fibril composed of amyloid protein. | ILX:0100586 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amyloid Precursor Protein | A membrane protein expressed in many tissues and concentrated in the synapses of neurons. It is implicated as a regulator of synapse formation and neural plasticity. Its proteolysis generates amyloid beta. | ILX:0100587 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amyloid Protein | Fibrous protein with insoluble fibrils that generally resist proteolytic digestion. | ILX:0100588 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amylose composition | A composition quality inhering in a bearer by virtue of the quantities or relative ratios of amylose in the inhering entity. | ILX:0100589 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Amyotrophic Lateral Sclerosis | A degenerative disorder affecting upper MOTOR NEURONS in the brain and lower motor neurons in the brain stem and SPINAL CORD. Disease onset is usually after the age of 50 and the process is usually fatal within 3 to 6 years. Clinical manifestations include progressive weakness, atrophy, FASCICULATION, hyperreflexia, DYSARTHRIA, dysphagia, and eventual paralysis of respiratory function. Pathologic features include the replacement of motor neurons with fibrous ASTROCYTES and atrophy of anterior SPINAL NERVE ROOTS and corticospinal tracts (MeSH). | ILX:0100590 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anabolic agent | A compound which stimulates anabolism and inhibits catabolism. Anabolic agents stimulate the development of muscle mass, strength, and power. | ILX:0100591 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anabolic steroid | ILX:0100592 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Anadoridoidea | ILX:0100593 | 4 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex | |
| Anaerobic | A quality inhering in a bearer by virtue of its independence from oxygen. | ILX:0100594 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anaerobic (for occurrence) | A quality inhering in a biological process by virtue of the process unfolding in a location without oxygen. | ILX:0100595 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anagrelide | Anagrelide is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It also has been used in the treatment of chronic myeloid leukemia. (Wikipedia) Pharmacology: Anagrelide is a drug used for the treatment of essential thrombocytosis (ET; essential thrombocythemia). It works by inhibiting the maturation of megakaryocytes into platelets. The exact mechanism of action is unclear, although it is known to be a potent (IC50 | ILX:0100596 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anakinra | Recombinant human interleukin-1 receptor antagonist. Has an extra Met at N-terminus, expressed in E. coli. 153 residues, MW | ILX:0100597 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Analysis service resource | A resource that provides a service, which transforms any input into data, such as producing gene expression profiles of a sample of tissue, or interpretation of EEG data. For example, the NIH blueprint core facility (La Jolla Core facility) can run certain types of experiments for researchers who do not wish to purchase equipment or develop expertise in the field. Viewing this as an input/output relationship the input would be a physical entity such as a mouse and the output would be data. | ILX:0100598 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
| Anaphylatoxin C3a | ILX:0100599 | 3 | scicrunch | 06/18/2018 | scicrunch | term | 12/08/2016 | 0 | NeuroLex | NeuroLex |
About
Base community for the SciCrunch.org infrastructure
Contact Us
X